Skip to main content

Table 1 Patient and treatment planning characteristics of all patients

From: Comparing biological effectiveness guided plan optimization strategies for cranial proton therapy: potential and challenges

Patient number

Diagnosis

Prescribed median dose/Gy(RBE)

Fx

Dose-limiting OARs

Treatment field angles (Gantry, Couch)

Primary CTV

Secondary CTV

1

Meningioma

54

30

Brainstem

(90°,310°)

(120°,0°)a

(70°,0°)a

2

Rosette-forming glioneuronal tumor, relapse

54

30

Opt. L + R, Chiasm, Brainstem

(90°,350°)a

(90°,190°)a

(90°,270°)

3

Meningioma

54

30

Opt. L + R, Chiasm, Brainstem

(90°,350°)a

(90°,320°)a

(90°,180°)

4

Meningioma

54

30

Opt. L, Chiasm, Brainstem

(90°,0°)a

(90°,320°)a

(90°,270°)

5

Meningioma

54

30

Opt. L + R, Chiasm, Brainstem

(290°,0°)a

(240°,0°)a

(90°,0°)

6

Chondrosarcoma

69.3

54.45

33

Opt. L + R, Chiasm, Brainstem

(90°,190°)a

(90°,350°)a

(90°,250°)

7

Adenoidcystic carcinoma

70

63

35

Opt. L, Chiasm, Brainstem

(240°,10°)a

(25°,0°)a

(105°,0°)

8

Clivus chordoma

73.5

56

35

Opt. L + R, Chiasm, Brainstem

(60°,0°)a

(120°,0°)a

(270°,0°)a

9

Chordoma

73.5

56

35

Opt. L + R, Chiasm, Brainstem

(100°,355°)a

(55°,290°)a

(240°,0°)

10

Clivus chordoma

73.5

56

35

Opt. L + R, Chiasm, Brainstem

(100°,0°)a

(250°, 5°)a

(60°,0°)a

  1. CTV clinical target volume, Fx fractions, OAR organ at risk, Opt optic nerve, L left, R right, a: with rangeshifter